Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...
Drug
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing...
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...
Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...
HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH
Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...
MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules
Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...
Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA
China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...
Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...
Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...